Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,361 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
2024年度独立董事述职报告(谭勇)
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report". It details the independent director's duties, attendance at meetings, communication with auditors, and oversight activities during the 2024 fiscal year. The content focuses on the independent director's report on their work and responsibilities rather than presenting financial statements or audit results. It is a formal report by a board member about their role and activities, which fits the category of Board/Management Information (MANG). The document is about the independent director's annual work report, not an announcement or a proxy statement, nor is it a full annual report or audit report. Therefore, the best classification is MANG with high confidence.
2025-04-25 Chinese
董事会审计委员会2024年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board of Directors Audit Committee 2024 Annual Performance Report" of a company. It details the audit committee's activities, meetings, evaluations of external auditors, internal audit guidance, internal control assessments, and overall performance for the year 2024. It is a report on the audit committee's duties and oversight rather than a full annual report or standalone audit report. The document length is 4130 characters, which is relatively short but contains substantive content about audit committee activities and evaluations. This fits the category of an Audit Report / Information (AR), which includes reports on audit committee activities and audit results but is not the full annual report. It is not an announcement or certification, so it is not RNS or RPA. Therefore, the best classification is AR with high confidence.
2025-04-25 Chinese
亚宝药业集团股份有限公司关于2024年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a profit distribution plan announcement for the fiscal year 2024 by 亚宝药业集团股份有限公司. It details the proposed cash dividend per share, the total dividend amount, and the approval process including board and supervisory opinions. The document is relatively short (1162 characters) and focuses on the dividend distribution plan rather than the full annual report or financial statements. It explicitly states that the plan will be submitted to the 2024 annual general meeting for approval. This type of document fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. It is not a full annual report (10-K), earnings release (ER), or other financial report. Therefore, the correct classification is DIV with high confidence.
2025-04-25 Chinese
亚宝药业集团股份有限公司关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (致同会计师事务所) for auditing the company's 2025 financial report and internal control audit. It details the qualifications, independence, and audit fees of the firm, as well as the board's approval and the need for shareholder approval at the 2024 annual general meeting. The document does not contain actual financial statements or audit results but is a formal announcement about the auditor appointment process. It is not an audit report itself, nor an annual or interim report. Given the content and length (2356 characters), this fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about auditor appointment rather than the audit report or financial report itself.
2025-04-25 Chinese
亚宝药业董事会审计委员会对会计师事务所2024年履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Audit Committee of 亚宝药业集团股份有限公司 regarding the supervision of the accounting firm 致同会计师事务所 for the year 2024. It discusses the audit firm's qualifications, the audit process, communication with management, and the audit results including the issuance of an unqualified audit opinion on the 2024 financial statements and internal controls. The document is not the audit report itself but a supervisory report on the audit firm's performance and the audit process. It is not an Annual Report (10-K) or Interim Report (IR) because it does not contain the full financial statements or comprehensive financial data but focuses on the audit oversight. It is not a simple announcement or certification but a substantive report on audit supervision. Therefore, the document fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and information about audit processes and results, excluding full annual reports. FY 2024
2025-04-25 Chinese
亚宝药业集团股份有限公司2024年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report". It includes detailed audit opinions, audit basis, key audit matters such as revenue recognition and inventory impairment testing, and the auditor's responsibilities. It also contains consolidated and company balance sheets, profit statements, cash flow statements, and notes to the financial statements. The document is comprehensive and contains actual financial data and audit analysis for the fiscal year ending December 31, 2024. This matches the definition of an Audit Report / Information (AR), which is a standalone audit report including applied accounting principles and audit results, distinct from a full Annual Report (10-K). The document is not merely an announcement or certification but a full audit report with substantive content.
2025-04-25 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.